A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation

Pharmaceutical Biology

Volumn 53, Issue 8, 2015, Pages 1110-1117

  Kulkarni, Nagaraj M ^a,b   Jaji, Mallikarjun S ^a   Shetty, Pranesha ^a   Kurhe, Yeshwant V ^a   Chaudhary, Shilpee ^a   Vijaykant, G ^a   Raghul, J ^a   Vishwakarma, Santosh L ^a   Rajesh, B Navin ^a   Mookkan, Jeyamurugan ^a   Krishnan, Uma Maheswari ^b   Narayanan, Shridhar ^b,c  

^a Orchid Chemicals and Pharmaceuticals Ltd   (India)

^b SASTRA UNIVERSITY   (India)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Animal model; Metabolic syndrome; Non alcoholic fatty liver disease (NAFLD); Nuclear factor kappa B; Oxazolone; Skin inflammation

Indexed keywords

FRUCTOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOPEROXIDASE; OXAZOLONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DERMATITIS; EAR EDEMA; ENZYME ACTIVITY; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERINSULINEMIA; LIPID DIET; MALE; METABOLIC SYNDROME X; MOUSE; MOUSE MODEL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PROTEIN EXPRESSION; SUGAR INTAKE; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; METABOLISM; PATHOLOGY;

ANIMALIA; MUS;

ANIMALS; DERMATITIS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84930794168     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2014.960944     Document Type: Article

References (23)

1. Almeda-Valdes P, Cuevas-Ramos D, Anguilar-Salinas CA. (2009). Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 8:S18-14.
2. Angulo P. (2002). Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-31.
3. Baker RG, Hayden MS, Ghosh S. (2011). NF-kB, inflammation and metabolic disease. Cell Metab 13:11-22.
4. Bell S, Degitz K, Quirling M, et al. (2003). Involvement of NF-kappaB signalling in skin physiology and disease. Cell Signal 15:1-7.
5. Bhatia LS, Curzen NP, Calder PC, Byrne CD. (2012). Non-alcoholic fatty liver disease: A new and important cardiovascular risk factor? Eur Heart J 33:1190-200.
6. Boehncke W, Hardt-Weinelt K, Nilsson H, et al. (2001). Anatagnoistic effects of the Staphylococcal Enterotoxin A mutant, SEA on psoriasis in SCID-hu xenogeneic transplantation model. J Invest Dermatol 116: 596-601.
7. Brunt EM, Tiniakos DG. (2002). Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol 16:691-707.
8. Cia D, Yuan M, Frantz DF, et al. (2005). Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NFkappaB. Nat Med 11:183-90.
9. De Vry CG, Valdez M, Lazarov M, et al. (2005). Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol 125: 473-81.
10. Folch J, Lees M, Stanley GHS. (1957). A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509.
11. Gerdes S, Rostami-Yazdi M, Mrowietz U. (2010). Adipokines and psoriasis. Exp Dermatol 20:81-7.
12. Gisondi P, Targher G, Zoppini G, Girolomoni G. (2009). Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 51:758-64.
13. Gottlieb AB, Chao C, Dann F. (2008). Psoriasis comorbidities. J Dermatol Treat 19:5-21.
14. Hamminga EA, Van Der Lely AJ, Neumann HAM, Thio HB. (2006). Chronic inflammation in psoriasis and obesity: Implications for therapy. Med Hypotheses 67:768-73.
15. Hubscher SG. (2006). Histological assessment of non-alcoholic fatty liver disease. Histopathology 49:450-65.
16. Li M, Zhong X, He Z, et al. (2012). Effect of erythromycin on cigaretteinduced histone deacetylase protein expression and nuclear factor-kB activity in human macrophages in vitro. Int Immunopharmacol 12: 643-50.
17. Marchesini G, Bugianesi E, Forlani G, et al. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-23.
18. Matsumoto T, Suziki N, Watanabe H, et al. (2004). Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J Gastroenterol 39: 1102-5.
19. Peterson TK. (2006). In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery. Basic Clin Pharmacol Toxicol 99:104-15.
20. Saraceno R, Ruzzetti M, De Martino MU, et al. (2008). Does metabolic syndrome influence psoriasis? Eur Rev Med Pharmacol Sci 12: 339-41
21. Tetri LH, Basaranoglu M, Brunt EM, et al. (2008). Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a highfructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295:G987-95.
22. Wenk KS, Arrington KC, Ehrlich A. (2010). Psoriasis and nonalcoholic fatty liver disease. J Eur Acad Dermatol Venereol 25: 383-91.
23. Yeom M, Kim S, Lee B, et al. (2012). Oral administration of glucosylceramide ameliorates inflammatory dry-skin condition in chronic oxazolone-induced irritant contact dermatitis in the mouse ear. J Dermatol Sci 67:101-10.